US Stock Insider Trading | Nuvalent Disclosed 10 Insider Transactions on March 16

K-LinePoet

2026-03-23 17:18:36

Abstract generation in progress

On March 16, 2026, Nuvalent (NUVL) disclosed 10 insider transactions. Executive Pelish Henry E. sold 24,200 shares on March 13, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 16, 2026	Executive	Pelish Henry E.	March 13, 2026	Sell	2,597	98.83	256,700
March 16, 2026	Executive	Pelish Henry E.	March 12, 2026	Buy	2,985	72.35	216,000
March 16, 2026	Executive	Pelish Henry E.	March 13, 2026	Sell	804	97.89	78,700
March 16, 2026	Executive	Pelish Henry E.	March 12, 2026	Sell	5,505	98.44	541,900
March 16, 2026	Executive	Pelish Henry E.	March 12, 2026	Buy	1,754	27.85	48,800
March 16, 2026	Executive	Pelish Henry E.	March 12, 2026	Buy	4,125	29.33	121,000
March 16, 2026	Executive	Pelish Henry E.	March 12, 2026	Buy	8,456	18.93	160,100
March 16, 2026	Executive	Pelish Henry E.	March 12, 2026	Sell	24,200	97.79	2,365,400
March 16, 2026	Executive	Pelish Henry E.	March 13, 2026	Sell	1,703	99.71	16,980
March 16, 2026	Executive	Pelish Henry E.	March 12, 2026	Sell	306	99.12	3,030

[Company Profile]

Nuvalent, Inc. was incorporated on January 25, 2017, under the laws of Delaware. The company is a clinical-stage biopharmaceutical company focused on developing precision targeted therapies for cancer patients. Leveraging the team’s deep expertise in chemistry and structure-based drug design, the company develops innovative small molecules aimed at overcoming limitations of existing therapies targeting clinically validated kinase targets. Current kinase inhibitors face potential limitations such as (i) kinase resistance, where mutations in kinase targets lead to resistance to existing therapies, (ii) kinase selectivity, where current therapies may inhibit structurally similar kinases causing off-target adverse events, and (iii) limited blood-brain barrier penetration, affecting the ability to treat diseases that have spread or metastasized to the brain.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes